55728-88-6

Basic information

• Product Name: penta-N-Cbz-paromomycin
• Synonyms: penta-N-Cbz-paromomycin
• CAS NO: 55728-88-6
• Molecular Weight: 1286.31
• Mol File: 55728-88-6.mol

Chemical Properties

• CAS DataBase Reference: penta-N-Cbz-paromomycin(CAS DataBase Reference)
• NIST Chemistry Reference: penta-N-Cbz-paromomycin(55728-88-6)
• EPA Substance Registry System: penta-N-Cbz-paromomycin(55728-88-6)

Safety Data

• Hazardous Substances Data: 55728-88-6(Hazardous Substances Data)

Upstream product

• 501-53-1 benzyl chloroformate 
• 7205-49-4 paromomycin sulfate 

Downstream Products

• 943967-10-0 2',1,3,2'''-tetra-N-benzyloxycarbonylparomomycin 
• 943967-11-1 C₆₇H₈₁N₅O₂₄ 
• 55728-89-7 4',6'-O-benzylidene-penta-N-benzyloxycarbonyl-paromomycin 
• 68405-95-8 O⁴-(O⁴,O⁶-(R)-benzylidene-2-benzyloxycarbonylamino-α-D-2-deoxy-glucopyranosyl)-O⁵-[O³-(N⁶,O⁴-(Ξ)-benzylidene-2,6-bis-benzyloxycarbonylamino-β-L-2,6-dideoxy-idopyranosyl)-β-D-ribofuranosyl]-N,N'-bis-benzyloxycarbonyl-1D-2-deoxy-streptamine 

Relevant articles and documents

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q1 and Q2 are as defined herein. Methods

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3 and Z1 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Ql, Q2, Rl, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS

The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.